- Home
- DRMA vs SPRC Comparison
DRMA vs SPRC Comparison
Compare DRMA & SPRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRMA
- SPRC
- Stock Information
- Founded
- DRMA 2014
- SPRC 2004
- Country
- DRMA United States
- SPRC Israel
- Employees
- DRMA N/A
- SPRC N/A
- Industry
- DRMA Biotechnology: Pharmaceutical Preparations
- SPRC Biotechnology: Pharmaceutical Preparations
- Sector
- DRMA Health Care
- SPRC Health Care
- Exchange
- DRMA Nasdaq
- SPRC Nasdaq
- Market Cap
- DRMA 3.5M
- SPRC 3.0M
- IPO Year
- DRMA 2021
- SPRC N/A
- Fundamental
- Price
- DRMA $5.48
- SPRC $4.63
- Analyst Decision
- DRMA Strong Buy
- SPRC
- Analyst Count
- DRMA 1
- SPRC 0
- Target Price
- DRMA $10.00
- SPRC N/A
- AVG Volume (30 Days)
- DRMA 28.3K
- SPRC 42.7K
- Earning Date
- DRMA 08-13-2025
- SPRC 01-01-0001
- Dividend Yield
- DRMA N/A
- SPRC N/A
- EPS Growth
- DRMA N/A
- SPRC N/A
- EPS
- DRMA N/A
- SPRC N/A
- Revenue
- DRMA N/A
- SPRC $1,306,000.00
- Revenue This Year
- DRMA N/A
- SPRC N/A
- Revenue Next Year
- DRMA N/A
- SPRC N/A
- P/E Ratio
- DRMA N/A
- SPRC N/A
- Revenue Growth
- DRMA N/A
- SPRC N/A
- 52 Week Low
- DRMA $5.09
- SPRC $4.00
- 52 Week High
- DRMA $24.90
- SPRC $37.59
- Technical
- Relative Strength Index (RSI)
- DRMA 37.22
- SPRC 35.46
- Support Level
- DRMA $5.09
- SPRC $4.13
- Resistance Level
- DRMA $6.09
- SPRC $4.90
- Average True Range (ATR)
- DRMA 0.52
- SPRC 0.52
- MACD
- DRMA -0.09
- SPRC -0.07
- Stochastic Oscillator
- DRMA 20.22
- SPRC 31.88
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
About SPRC SciSparc Ltd.
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.